The Latest Cardiac and Vascular News
Silence Therapeutics Initiates Dosing in Phase 1 Clinical Trial of SLN360 for Cardiovascular Disease Due to High Lipoprotein(a) 17 February 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics […]
Transformative Technology Now Available for Calcified Coronary Plaque SANTA CLARA, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company’s sonic pressure wave therapy received Pre-Market Approval for […]
Rajagopalan to be presented with the Distinguished Scientist Award – Translational Domain during ACC’s 70th Annual Scientific Session CLEVELAND — Sanjay Rajagopalan, MD, FACC, has been awarded the 2021 Distinguished Scientist Award – Translational Domain by the American College of Cardiology (ACC) for his contributions to the cardiovascular profession. Dr. […]
New patent covers updated aerosol delivery system and design until 2039 WARRINGTON, Pa., Feb. 16, 2021 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that the United States Patent and Trademark Office (USPTO) […]
Advocates Continue to Drive Forward Heart Valve Disease Awareness, While Highlighting the Inequities in Risk Factors, Diagnosis, and Treatment Faced by Black Americans WASHINGTON, Feb. 16, 2021 /PRNewswire/ — On Monday, February 22, more than 90 national organizations and thousands of patient advocates will recognize the fifth anniversary of the annual HVD Awareness Day (“Valve Disease […]
ELK GROVE VILLAGE, Ill., Feb. 16, 2021 /PRNewswire/ — Orsini Specialty Pharmacy, a leader in rare diseases and gene therapies, announced today that it has been selected by Regeneron Pharmaceuticals, Inc. as the exclusive specialty pharmacy partner for EvkeezaTM (evinacumab-dgnb). Evkeeza is approved by the U.S. Food and Drug Administration (FDA) as an adjunct […]
BioSerenity acquires Cardioskin™ global distribution rights PARIS and ATLANTA, Feb. 16, 2021 /PRNewswire/ — WeHealth™ Digital Medicine (e-health division of the Servier Group) and BioSerenity announced today that BioSerenity gains global distribution rights for Cardioskin™, the first WeHealth™ digital Solution co-developped with a start-up, to accelerate the commercialization of Cardioskin™. After successfully collaborating to develop the Cardioskin™, the […]
Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction (HFrEF) and many with heart failure with preserved ejection fraction (HFpEF)1-3 Expanded indication enables potential treatment of more adults with […]
The favorable opinion of the CPP (French ethic committee) and authorization from the ANSM (French National Agency for the Safety of Medicines and Health Products) allow the operational launch of the HEART study. The HEART study will be conducted under the scientific expertise of Jean-Marie Bard, Professor and Hospital Practitioner […]
New Patents to Support Global Partnering of Novel Bio-inspired Clot-dissolving Therapy CAMBRIDGE, MA, February 10, 2021 / B3C newswire / — Thrombolytic Science, LLC (TSI) today announced the granting of three new patents during the last 12 months. The invention relates to methods and compositions for safe and effective thrombolysis for ischemic […]
